Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo

Abstract Cryptococcal pneumonia is a severe fungal infection of the respiratory system, predominantly caused by Cryptococcus neoformans. Its incidence is increasing, driven by evolving pathogen dynamics and heightened susceptibility among patient populations. This investigation aimed to assess the c...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhao Yu, Zhihao Liu, Jiaojiao Qian, Yuanyuan Qian
Format: Article
Language:English
Published: SpringerOpen 2025-01-01
Series:AMB Express
Subjects:
Online Access:https://doi.org/10.1186/s13568-025-01827-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832571212343017472
author Zhao Yu
Zhihao Liu
Jiaojiao Qian
Yuanyuan Qian
author_facet Zhao Yu
Zhihao Liu
Jiaojiao Qian
Yuanyuan Qian
author_sort Zhao Yu
collection DOAJ
description Abstract Cryptococcal pneumonia is a severe fungal infection of the respiratory system, predominantly caused by Cryptococcus neoformans. Its incidence is increasing, driven by evolving pathogen dynamics and heightened susceptibility among patient populations. This investigation aimed to assess the combined therapeutic efficacy of Fluconazole and Amphotericin B for cryptococcal pneumonia and to explore the roles of miR-15b and TGF-β1 in modulating treatment response. Twenty-eight patients diagnosed with cryptococcal pneumonia were randomly allocated to receive either Amphotericin B monotherapy (control group) or a combination of Amphotericin B and Fluconazole (observation group) over a 14-day period. Key respiratory function indices—forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratios—were measured pre- and post-treatment, alongside levels of procalcitonin (PCT), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), miR-15b, and TGF-β1. Results demonstrated marked improvements in pulmonary function within the observation group, with significantly higher FEV1, FVC, and FEV1/FVC values than those in the control group (P < 0.05). Additionally, the observation group exhibited greater reductions in PCT and sTREM-1, coupled with notable elevations in miR-15b and TGF-β1 levels. The combination therapy achieved a total response rate of 92.86%, significantly surpassing the control’s 57.14% efficacy (P < 0.05). These findings indicate that Fluconazole combined with Amphotericin B not only enhances clinical efficacy by mitigating inflammation but also supports lung function recovery with a favourable safety profile, highlighting its utility in managing cryptococcal pneumonia effectively.
format Article
id doaj-art-08c4e60605ae4e0089807a902a51abec
institution Kabale University
issn 2191-0855
language English
publishDate 2025-01-01
publisher SpringerOpen
record_format Article
series AMB Express
spelling doaj-art-08c4e60605ae4e0089807a902a51abec2025-02-02T12:43:54ZengSpringerOpenAMB Express2191-08552025-01-011511710.1186/s13568-025-01827-3Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivoZhao Yu0Zhihao Liu1Jiaojiao Qian2Yuanyuan Qian3Department of Emergency, Haining Branch, The First Affiliated Hospital of Zhejiang University School of MedicineDepartment of Respiratory and Critical Care, Haining Branch, The First Affiliated Hospital of Zhejiang University School of MedicineDepartment of Obstetrics and Gynecology, Liangzhu Branch, The First Affiliated Hospital of Zhejiang University School of MedicineDepartment of Respiratory and Critical Care, Haining Branch, The First Affiliated Hospital of Zhejiang University School of MedicineAbstract Cryptococcal pneumonia is a severe fungal infection of the respiratory system, predominantly caused by Cryptococcus neoformans. Its incidence is increasing, driven by evolving pathogen dynamics and heightened susceptibility among patient populations. This investigation aimed to assess the combined therapeutic efficacy of Fluconazole and Amphotericin B for cryptococcal pneumonia and to explore the roles of miR-15b and TGF-β1 in modulating treatment response. Twenty-eight patients diagnosed with cryptococcal pneumonia were randomly allocated to receive either Amphotericin B monotherapy (control group) or a combination of Amphotericin B and Fluconazole (observation group) over a 14-day period. Key respiratory function indices—forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratios—were measured pre- and post-treatment, alongside levels of procalcitonin (PCT), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), miR-15b, and TGF-β1. Results demonstrated marked improvements in pulmonary function within the observation group, with significantly higher FEV1, FVC, and FEV1/FVC values than those in the control group (P < 0.05). Additionally, the observation group exhibited greater reductions in PCT and sTREM-1, coupled with notable elevations in miR-15b and TGF-β1 levels. The combination therapy achieved a total response rate of 92.86%, significantly surpassing the control’s 57.14% efficacy (P < 0.05). These findings indicate that Fluconazole combined with Amphotericin B not only enhances clinical efficacy by mitigating inflammation but also supports lung function recovery with a favourable safety profile, highlighting its utility in managing cryptococcal pneumonia effectively.https://doi.org/10.1186/s13568-025-01827-3Amphotericin BCryptococcal pneumoniaCryptococcus neoformansFluconazoleMicroRNA-15b
spellingShingle Zhao Yu
Zhihao Liu
Jiaojiao Qian
Yuanyuan Qian
Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo
AMB Express
Amphotericin B
Cryptococcal pneumonia
Cryptococcus neoformans
Fluconazole
MicroRNA-15b
title Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo
title_full Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo
title_fullStr Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo
title_full_unstemmed Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo
title_short Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo
title_sort effects of fluconazole and amphotericin b in the control of cryptococcal pneumonia in vivo
topic Amphotericin B
Cryptococcal pneumonia
Cryptococcus neoformans
Fluconazole
MicroRNA-15b
url https://doi.org/10.1186/s13568-025-01827-3
work_keys_str_mv AT zhaoyu effectsoffluconazoleandamphotericinbinthecontrolofcryptococcalpneumoniainvivo
AT zhihaoliu effectsoffluconazoleandamphotericinbinthecontrolofcryptococcalpneumoniainvivo
AT jiaojiaoqian effectsoffluconazoleandamphotericinbinthecontrolofcryptococcalpneumoniainvivo
AT yuanyuanqian effectsoffluconazoleandamphotericinbinthecontrolofcryptococcalpneumoniainvivo